Septerna, Inc. Common Stock (SEPN)vsVertex Pharmaceuticals Inc (VRTX)
SEPN
Septerna, Inc. Common Stock
$24.21
+3.28%
HEALTHCARE · Cap: $1.09B
VRTX
Vertex Pharmaceuticals Inc
$454.97
+1.42%
HEALTHCARE · Cap: $113.95B
Smart Verdict
WallStSmart Research — data-driven comparison
Vertex Pharmaceuticals Inc generates 26018% more annual revenue ($12.00B vs $45.95M). VRTX leads profitability with a 32.9% profit margin vs -106.4%. VRTX earns a higher WallStSmart Score of 66/100 (B-).
SEPN
Avoid33
out of 100
Grade: F
VRTX
Strong Buy66
out of 100
Grade: B-
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for SEPN.
Margin of Safety
+36.5%
Fair Value
$716.04
Current Price
$454.97
$261.07 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Revenue surging 112.8% year-over-year
Conservative balance sheet, low leverage
Safe zone — low bankruptcy risk
Reasonable price relative to book value
Keeps 33 of every $100 in revenue as profit
Strong operational efficiency at 39.6%
Safe zone — low bankruptcy risk
Large-cap with strong market position
Every $100 of equity generates 23 in profit
Conservative balance sheet, low leverage
Areas to Watch
0.0% earnings growth
Smaller company, higher risk/reward
ROE of -12.2% — below average capital efficiency
Negative free cash flow — burning cash
Expensive relative to growth rate
Moderate valuation
Weak financial health signals
Comparative Analysis Report
WallStSmart ResearchBull Case : SEPN
The strongest argument for SEPN centers on Revenue Growth, Debt/Equity, Altman Z-Score. Revenue growth of 112.8% demonstrates continued momentum.
Bull Case : VRTX
The strongest argument for VRTX centers on Profit Margin, Operating Margin, Altman Z-Score. Profitability is solid with margins at 32.9% and operating margin at 39.6%.
Bear Case : SEPN
The primary concerns for SEPN are EPS Growth, Market Cap, Return on Equity.
Bear Case : VRTX
The primary concerns for VRTX are PEG Ratio, P/E Ratio, Piotroski F-Score.
Key Dynamics to Monitor
SEPN profiles as a hypergrowth stock while VRTX is a mature play — different risk/reward profiles.
SEPN is growing revenue faster at 112.8% — sustainability is the question.
VRTX generates stronger free cash flow (349M), providing more financial flexibility.
Monitor BIOTECHNOLOGY industry trends, competitive dynamics, and regulatory changes.
Bottom Line
VRTX scores higher overall (66/100 vs 33/100), backed by strong 32.9% margins. Both earn "Strong Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Septerna, Inc. Common Stock
HEALTHCARE · BIOTECHNOLOGY · USA
Septerna, Inc. is an innovative biotechnology company at the forefront of developing transformative therapeutics via selective protein modulation. With a commitment to addressing unmet medical needs across diverse disease areas, Septerna leverages proprietary platforms and deep scientific acumen to advance a robust pipeline of next-generation drug candidates. The company's strategic focus on research and development, coupled with its potential for significant clinical impact, positions it as a compelling opportunity for institutional investors seeking exposure in the dynamic biopharmaceutical sector.
Visit Website →Vertex Pharmaceuticals Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Vertex Pharmaceuticals, Inc. is an American biopharmaceutical company based in Boston, Massachusetts.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?